JP Morgan Chase’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5
| Closed | -$25 | – | 7886 |
|
|
2024
Q1 | $25 | Sell |
5
-1
| -17% | -$6 | ﹤0.01% | 7145 |
|
|
2023
Q4 | $37 | Sell |
6
-274
| -98% | -$2.41K | ﹤0.01% | 7251 |
|
|
2023
Q3 | $2.56K | Sell |
280
-4,512
| -94% | -$90.7K | ﹤0.01% | 6505 |
|
|
2023
Q2 | $101K | Sell |
4,792
-2,897
| -38% | -$89.2K | ﹤0.01% | 5456 |
|
|
2023
Q1 | $207K | Buy |
7,689
+3,938
| +105% | +$183K | ﹤0.01% | 5049 |
|
|
2022
Q4 | $133K | Sell |
3,751
-63
| -2% | -$7.57K | ﹤0.01% | 5228 |
|
|
2022
Q3 | $862K | Sell |
3,814
-8
| -0.2% | -$1.97K | ﹤0.01% | 4115 |
|
|
2022
Q2 | $722K | Buy |
3,822
+85
| +2% | +$17.1K | ﹤0.01% | 4324 |
|
|
2022
Q1 | $931K | Sell |
3,737
-100
| -3% | -$15.8K | ﹤0.01% | 4327 |
|
|
2021
Q4 | $598K | Sell |
3,837
-32
| -0.8% | -$6.19K | ﹤0.01% | 4711 |
|
|
2021
Q3 | $775K | Sell |
3,869
-730
| -16% | -$174K | ﹤0.01% | 4482 |
|
|
2021
Q2 | $1.18M | Buy |
4,599
+333
| +8% | +$83.1K | ﹤0.01% | 4184 |
|
|
2021
Q1 | $1.13M | Sell |
4,266
-2,517
| -37% | -$793K | ﹤0.01% | 4129 |
|
|
2020
Q4 | $2.5M | Buy |
6,783
+94
| +1% | +$27K | ﹤0.01% | 3324 |
|
|
2020
Q3 | $1.66M | Sell |
6,689
-3,659
| -35% | -$1.14M | ﹤0.01% | 3355 |
|
|
2020
Q2 | $2.98M | Buy |
10,348
+535
| +5% | +$158K | ﹤0.01% | 2843 |
|
|
2020
Q1 | $2M | Sell |
9,813
-1,257
| -11% | -$401K | ﹤0.01% | 2967 |
|
|
2019
Q4 | $4.95M | Buy |
11,070
+814
| +8% | +$289K | ﹤0.01% | 2681 |
|
|
2019
Q3 | $3.15M | Buy |
10,256
+9,197
| +868% | +$2.99M | ﹤0.01% | 3086 |
|
|
2019
Q2 | $340K | Sell |
1,059
-581
| -35% | -$201K | ﹤0.01% | 4414 |
|
|
2019
Q1 | $688K | Buy |
+1,640
| New | +$658K | ﹤0.01% | 4021 |
|
|
2018
Q4 | – | Sell |
-2,575
| Closed | -$927K | – | 5993 |
|
|
2018
Q3 | $927K | Buy |
2,575
+1,312
| +104% | +$449K | ﹤0.01% | 3967 |
|
|
2018
Q2 | $462K | Buy |
+1,263
| New | +$450K | ﹤0.01% | 4209 |
|
|
2018
Q1 | – | Sell |
-431
| Closed | -$180K | – | 5683 |
|
|
2017
Q4 | $180K | Buy |
431
+41
| +11% | +$14.7K | ﹤0.01% | 4456 |
|
|
2017
Q3 | $126K | Buy |
390
+291
| +294% | +$79.3K | ﹤0.01% | 4241 |
|
|
2017
Q2 | $23K | Buy |
99
+7
| +8% | +$1.59K | ﹤0.01% | 4514 |
|
|
2017
Q1 | $32K | Sell |
92
-34
| -27% | -$11.7K | ﹤0.01% | 4630 |
|
|
2016
Q4 | $44K | Buy |
+126
| New | +$46.2K | ﹤0.01% | 4585 |
|
|
2015
Q2 | – | Sell |
-379
| Closed | -$3.23M | – | 4225 |
|
|
2015
Q1 | $3.23M | Buy |
379
+5
| +1% | +$43.7K | ﹤0.01% | 2616 |
|
|
2014
Q4 | $3.29M | Buy |
374
+130
| +53% | +$754K | ﹤0.01% | 2669 |
|
|
2014
Q3 | $1.15M | Sell |
244
-8
| -3% | -$42.3K | ﹤0.01% | 3250 |
|
|
2014
Q2 | $1.81M | Sell |
252
-910
| -78% | -$4.55M | ﹤0.01% | 2583 |
|
|
2014
Q1 | $6.23M | Buy |
+1,162
| New | +$5.49M | ﹤0.01% | 1963 |
|
Other funds holding EIGR
JP Morgan Chase's EIGR Position: Q2 2024 in Review
JP Morgan Chase sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 5 shares — an estimated $25 sold.
JP Morgan Chase first reported a position in EIGR in Q1 2014 and held it in 33 quarters. The position peaked at $6.23M in Q1 2014. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- JP Morgan Chase reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 5 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $25.
- JP Morgan Chase first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- JP Morgan Chase's Eiger BioPharmaceuticals, Inc. position peaked at $6.23M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.